氩气冷等离子体——治疗难治性角膜感染的新工具
本研究为首次人体病例系列与实验研究,检测氩气冷等离子体对原代人角膜缘上皮细胞活性的影响、对常见病原体的消毒潜力,并治疗4例难治性角膜溃疡患者;结果显示0.5-5分钟暴露后细胞24小时内完全恢复,所有病原体均对冷等离子体敏感,4例患者病情显著改善。
要点
- 0.5-5分钟冷等离子体处理后角膜上皮细胞24小时内完全恢复,仅10分钟处理造成永久损伤。
- 所有受试病原体均对冷等离子体敏感,但敏感性水平不同。
- 4例难治性角膜溃疡患者经冷等离子体联合抗生素治疗后病情显著改善。
核心结论
- 氩气冷等离子体治疗在体外、离体和患者眼部直接应用中均可减少或消除常见病原体而不损伤角膜上皮细胞。
- 作者认为氩气冷等离子体疗法为难治性角膜感染提供了潜在的补充或替代疗法。
- 作者指出需要更大规模、对照研究进一步证实这些发现。
研究设计与样本
- 首次人体病例系列与实验研究。
- 检测冷等离子体对原代人角膜缘上皮细胞活性的影响,暴露时间为0.5至10分钟,评估代谢活性、氧化应激和凋亡。
- 在培养基上检测冷等离子体对金黄色葡萄球菌、表皮葡萄球菌、大肠杆菌、铜绿假单胞菌和白色念珠菌的消毒潜力,通过菌落形成单位计数和光密度测量评估,并在人角膜感染模型中针对金黄色葡萄球菌检测。
- 首次人体试验中治疗4例难治性角膜溃疡患者以评估冷等离子体的临床潜力。
主要发现
- 0.5-5分钟处理的细胞在24小时内完全恢复且形态无变化,仅10分钟处理造成细胞永久损伤。
- 未发现明显的氧化应激、凋亡或角膜结构损伤。
- 所有病原体均对冷等离子体处理敏感,敏感性水平不同。
- 4例患者经冷等离子体联合抗生素治疗后病情均显著改善。
关键数值与推荐
- 细胞暴露时间0.5至10分钟;0.5-5分钟处理后细胞24小时内完全恢复,10分钟处理造成永久损伤。
- 受试病原体包括金黄色葡萄球菌、表皮葡萄球菌、大肠杆菌、铜绿假单胞菌和白色念珠菌。
- 首次人体试验纳入4例难治性角膜溃疡患者。
临床怎么用
- 作者认为氩气冷等离子体疗法为难治性角膜感染提供了潜在的补充或替代疗法。
- 作者指出需要更大规模、对照研究进一步证实这些发现。
局限性
- 作者指出需要更大规模、对照研究进一步证实这些发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To test whether therapy-resistant corneal infections can be successfully treated with argon cold plasma to reduce or eliminate pathogen microorganisms without affecting corneal cell viability. DESIGN: First-in-human case series and experimental study. METHODS: Cold plasma effects on viability of primary human corneal limbal epithelial cells were studied using exposure times from 0.5 to 10 minutes (metabolic activity, oxidative stress, apoptosis). Disinfective potential of cold plasma was tested against common pathogens (Staphylococcus aureus, Staphylococcus epidermidis, Escherichia coli, Pseudomonas aeruginosa, and Candida albicans) on culture medium and evaluated by counting colony-forming units and optical density measurements, as well as against S aureus in a human cornea infection model. Additionally, in a first-in-human trial 4 patients with therapy-resistant corneal ulcers were treated to evaluate the clinical potential of cold plasma. RESULTS: Cells treated for 0.5-5 minutes completely recovered within 24 hours without changes in morphology; only 10-minute treatment impaired the cells permanently. No evident oxidative stress, apoptosis, or damage to the corneal structure could be found. All pathogens were susceptible to cold plasma treatments, with different levels of sensitivity. The condition of all 4 patients significantly improved after cold plasma treatment combined with antibiotic therapy. CONCLUSIONS: Our results indicate that argon cold plasma treatment reduces or eliminates common pathogens without impairing corneal epithelial cells in vitro, ex vivo, and in direct application on patients' eyes. We conclude that argon cold plasma therapy offers a potential supplement or alternative therapy for therapy-resistant corneal infections. A larger, comparative study is necessary to further confirm these findings.
引用
- Reitberger HH, Czugala M, Chow C, et al. Argon Cold Plasma-A Novel Tool to Treat Therapy-resistant Corneal Infections. Am J Ophthalmol. 2018. PMID: 29580975. doi:10.1016/j.ajo.2018.03.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。